<DOC>
<DOCNO>
EP-0004589
</DOCNO>
<TEXT>
<DATE>
19791017
</DATE>
<IPC-CLASSIFICATIONS>
C07K-5/00 C07K-5/065 C07C-231/00 G01N-33/487 G01N-33/48 C07K-5/06 C12Q-1/37 <main>C07C-103/52</main> C07C-67/00 G01N-33/493 
</IPC-CLASSIFICATIONS>
<TITLE>
alpha-n-acetyl-l-phenylalanine-l-arginine-ethyl ester, process for its preparation and its use as a diagnostic agent for kallikrein.
</TITLE>
<APPLICANT>
bayer agde<sep>bayer aktiengesellschaft<sep>bayer ag51368 leverkusende<sep>bayer ag<sep>
</APPLICANT>
<INVENTOR>
fiedler franz dr<sep>fiedler, franz, dr.<sep>fiedler, franz, dr.reisingerstrasse 15d-8000 muenchen 15de<sep>fiedler, franz, dr.<sep>fiedler, franz, dr.reisingerstrasse 15d-8000 muenchen 15de<sep>
</INVENTOR>
<ABSTRACT>
The present invention relates to the new dipeptide derivative Î±-N-acetyl-L-phenylalanyl-L-arginine ethyl ester (abbreviated spelling: AC-Phe-Arg OET) and its acid addition salts as well as its use as a calipulein substrate, preferably in the context of a diagnostic arrangementTo determine the Kallikrein content, preferably small caliprein quantities, such as it z.b.In urine or saliva occur.
</ABSTRACT>
</TEXT>
</DOC>
